Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition

Executive Summary

WellPoint will not take legal action against FDA should the agency reject the health insurer's citizen petition to force an OTC switch of prescription low- and non-sedating antihistamines

You may also be interested in...



WellPoint Swears Off Switch Petitions; Antihistamine Campaign Had PR Costs

The adverse publicity surrounding WellPoint's petition to force an OTC switch of nonsedating antihistamines has convinced the insurer not to pursue similar efforts in the future, WellPoint Health Networks Chief Pharmacy Officer Robert Seidman told a recent IIR conference in Philadelphia

WellPoint Swears Off Switch Petitions; Antihistamine Campaign Had PR Costs

The adverse publicity surrounding WellPoint's petition to force an OTC switch of nonsedating antihistamines has convinced the insurer not to pursue similar efforts in the future, WellPoint Health Networks Chief Pharmacy Officer Robert Seidman told a recent IIR conference in Philadelphia

Zocor OTC Switch Sought In U.K.; Merck’s First Choice For U.S. Is Mevacor

Merck continues to favor Mevacor as its primary OTC switch candidate for the U.S. statin market despite a favorable recommendation by the British Department of Health to sell Zocor over the counter in the U.K

Related Content

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel